BCL-6 and rituximab in diffuse large B-cell lymphoma: where are we?

Blood. 2007 Jan 15;109(2):843-4; discussion 844-5. doi: 10.1182/blood-2006-07-038000.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cyclophosphamide / therapeutic use
  • DNA-Binding Proteins / genetics*
  • Doxorubicin / therapeutic use
  • Follow-Up Studies
  • Gene Expression Regulation, Leukemic / genetics
  • Humans
  • Lymphoma, B-Cell / drug therapy*
  • Lymphoma, B-Cell / genetics*
  • Lymphoma, Large B-Cell, Diffuse / drug therapy*
  • Lymphoma, Large B-Cell, Diffuse / genetics*
  • Prednisone / therapeutic use
  • Proto-Oncogene Proteins c-bcl-6
  • RNA, Messenger / biosynthesis
  • RNA, Messenger / genetics
  • Rituximab
  • Treatment Outcome
  • Vincristine / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • BCL6 protein, human
  • DNA-Binding Proteins
  • Proto-Oncogene Proteins c-bcl-6
  • RNA, Messenger
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • CHOP protocol